Clinical-stage biopharmaceutical company VistaGen Therapeutics (NASDAQ: VTGN) recently announced that it has been issued U.S. Patent No. 9,834,801 by the U.S. Patent and Trademark Office (“USPTO”), strengthening its intellectual property (“IP”) stance. The newly-issued patent covers certain methods of production for AV-101, VistaGen’s lead central nervous system (“CNS”) product candidate. “This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential,” VistaGen CEO Shawn Singh stated in the news release.
To view the full press release, visit http://nnw.fm/nFvL2
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen’s lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101’s mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants, with Dr. Maurizio Fava of Harvard University as Principal Investigator. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington’s disease, Parkinson’s disease levodopa-induced dyskinesia and other disorders where modulation of the NMDA receptors, activation of the AMPA neurotransmitter pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit. For more information, visit the company’s website at www.VistaGen.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com